Cell Cure Neurosciences, an Israeli company which develops stem cell based treatments for degenerative diseases, has raised $3.5 million via share swap with BioTime Inc. The investment reflects a company value of $15.1 million for Cell Cure, and assures BioTime an ownership of 62 percent.
Related posts
People With Autism Experience Higher Intensity Pain
January 30, 2023
Israeli Innovation At New Bahraini Hospital
January 30, 2023
US Car Giant Signs Up For AI Vehicle Inspections
January 29, 2023
Considerate Partners Are Less Likely To Cheat
January 29, 2023
Facebook comments